ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.306,90
-0,21%
S&P 500
5.909,03
0,00%
Dow Jones
42.528,36
0,00%
Euro vs US Dollar
1,02986
-0,44%
Bitcoin
95.433,54
-1,52%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Prevail Therapeutics Inc (PRVL) Börsenkurse

Prevail Therapeutics Inc

Prevail Therapeutics Inc (PRVL)

Porvair PLC
Porvair PLC
Porvair PLC
23,00
0,00
(0,00%)
Geschlossen 08 Januar 10:00PM
Verzögert um 15 Minuten
23,00
0,00
( 0,00% )
Vor Marktöffnung: 1:00AM
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
23,00
Gebot
24,00
Fragen
23,00
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Handelsende
23,00
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Durchschnittliches Volumen (3 Mio.)
-
Finanzvolumen
-
VWAP
-

PRVL Neueste Nachrichten

Weitere Nachrichten

Lilly Completes Acquisition of Prevail Therapeutics

Lilly Completes Acquisition of Prevail Therapeutics PR Newswire INDIANAPOLIS, Jan. 22, 2021 INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the...

22 Januar 2021
PR Newswire (US)

Lilly Announces Agreement to Acquire Prevail Therapeutics

Lilly Announces Agreement to Acquire Prevail Therapeutics Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden...

15 Dezember 2020
PR Newswire (US)

Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of...

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

11 Dezember 2020
GlobeNewswire Inc.

Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

30 November 2020
GlobeNewswire Inc.

Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

19 November 2020
GlobeNewswire Inc.

Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE Trial of PR001 for Type 2 Gaucher Disease and Phase 1/2 PROCLAIM...

13 November 2020
GlobeNewswire Inc.

Prevail Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

10 November 2020
GlobeNewswire Inc.

Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

02 November 2020
GlobeNewswire Inc.

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease

NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

27 Oktober 2020
GlobeNewswire Inc.

Prevail Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

25 September 2020
GlobeNewswire Inc.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

PRVL - Frequently Asked Questions (FAQ)

What is the current Prevail Therapeutics share price?
The current share price of Prevail Therapeutics is US$ 23,00
What is the 1 year trading range for Prevail Therapeutics share price?
Prevail Therapeutics has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
SANASana Biotechnology Inc
US$ 6,1099
(270,30%)
27,41M
CURRCurrenc Group Inc
US$ 2,97
(113,67%)
40,14M
ACCDAccolade Inc
US$ 6,8598
(104,77%)
356,14k
SILOSilo Pharma Inc
US$ 2,08
(90,83%)
19,07M
VIRVir Biotechnology Inc
US$ 12,65
(60,33%)
5,82M
DATSDatChat Inc
US$ 3,90
(-56,33%)
2,59M
JSPRJasper Therapeutics Inc
US$ 9,00
(-49,18%)
1,2M
XTIAXTI Aerospace Inc
US$ 0,0609
(-46,63%)
85,5M
AMPGAmplitech Group Inc
US$ 2,45
(-32,51%)
2,3M
RIMEAlgorhythm Holdings Inc
US$ 0,1543
(-32,03%)
10,7M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,1278
(11,13%)
152,54M
GCTKGlucoTrack Inc
US$ 0,17
(9,68%)
108,7M
XTIAXTI Aerospace Inc
US$ 0,0609
(-46,63%)
85,5M
CURRCurrenc Group Inc
US$ 2,97
(113,67%)
40,14M
SVMHSRIVARU Holding Ltd
US$ 0,06485
(-22,80%)
32,06M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
PRVL
Prevail Therapeutics
TG
5ZK
Quest Resource
BIT
UC6MQU
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten